中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(5): 1132-1136

Association between liver fibrosis and C-peptide in patients with type 2 diabetes and nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.05.030

  • Department of Geriatrics, The Second Hospital of Lanzhou University, Lanzhou 730000, China

  • Received Date: 2020-10-16
  • Accepted Date: 2020-11-17
  • Published Date: 2021-05-20
    Abstract
  •   Objective  To investigate the effect of serum C-peptide level on the progression of liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).  Methods  A total of 484 patients with T2DM who were admitted to Department of Geriatrics, The Second Hospital of Lanzhou University, from December 2018 to July 2020 were enrolled, and according to the results of abdominal ultrasound examination, they were divided into simple T2DM group with 107 patients and T2DM+NAFLD group with 377 patients. According to NAFLD fibrosis score, the patients with T2DM and NAFLD were divided into fibrosis exclusion subgroup (T2DM+F0) with 136 patients, uncertain subgroup (T2DM+F1) with 146 patients, and fibrosis subgroup (T2DM+F2) with 95 patients. Medical history data and laboratory markers were collected. The chi-square test was used for comparison of categorical data; the t-test or the Mann-Whitney U test was used for comparison of continuous data, and a one-way analysis of variance or the Kruskal-Wallis H test was used for comparison between multiple groups; a logistic regression analysis was used to explore the risk factors for the progression of liver fibrosis; the receiver operating characteristic (ROC) curve was used to analyze the clinical value of serum C-peptide in predicting and diagnosing the progression of liver fibrosis.  Results  Compared with the simple T2DM group, the T2DM+NAFLD group had a significant increase in C-peptide level (Z=-6.040, P < 0.001); compared with the T2DM+F1 and T2DM+F0, the T2DM+F2 had significantly higher C-peptide level [2.89 (1.84-3.77) vs 1.97 (1.12-2.65)/1.87 (1.25-2.68), H=36.023, P < 0.001) and rate of fasting C-peptide (56.84% vs 23.29%/24.27%, χ2=37.583, P < 0.001). The logistic regression analysis showed that C-peptide (OR=1.435, 95% confidence interval: 1.227~1.678, P < 0.001) was a risk factor for liver fibrosis in patients with T2DM and NAFLD, and the ROC curve analysis also showed that C-peptide had great significance in predicting liver fibrosis in such patients, with an area under the ROC curve of 0.814, a sensitivity of 64.2%, a specificity of 89.7%, and a Youden index of 0.539 at the optimal cut-off value of 2.405 ng/ml.  Conclusion  C-peptide is an independent risk factor for the progression of liver fibrosis in patients with T2DM and NAFLD.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [2]
    ARRESE M, BARRERA F, TRIANTAFILO N, et al. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: Diagnostic and therapeutic considerations[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(9): 849-866. DOI: 10.1080/17474124.2019.1649981.
    [3]
    BRIL F, CUSI K. Management of Nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action[J]. Diabetes Care, 2017, 40(3): 419-430. DOI: 10.2337/dc16-1787.
    [4]
    TARGHER G, LONARDO A, BYRNE CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Nat Rev Endocrinol, 2018, 14(2): 99-114. DOI: 10.1038/nrendo.2017.173.
    [5]
    ZHANG YC, LI W. Association between diabetes and nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(10): 2329-2332. DOI: 10.3969/j.issn.1001-5256.2020.10.037.

    张永超, 李威. 糖尿病和非酒精性脂肪性肝病相关肝细胞癌的相互关系[J]. 临床肝胆病杂志, 2020, 36(10): 2329-2332. DOI: 10.3969/j.issn.1001-5256.2020.10.037.
    [6]
    Chinese Diabetes Society, Chinese Medical Association. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition)[J]. Chin J Diabetes, 2018, 10(1): 4-67. DOI: 10.3760/cma.j.issn.1674-5809.2018.01.003.

    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67. DOI: 10.3760/cma.j.issn.1674-5809.2018.01.003.
    [7]
    National Workshop on Fatty Liver and Alcoholic Liver Disease Chinese Society of Hepatology Chinese Medical Association; Fatty Liver Expert Committee Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [8]
    DING Y, FU Q, QIN Y, et al. Analysis of islet beta cell function assessed by C-peptide changing with the disease duration in patients with type 2 diabetes mellitus[J]. Chin J Diabetes, 2020, 12(7): 491-495. DOI: 10.3760/cma.j.cn115791-20200403-00185.

    丁宇, 付麒, 秦瑶, 等. 2型糖尿病患者C肽评估胰岛β细胞功能随病程变化的分析[J]. 中华糖尿病杂志, 2020, 12(7): 491-495. DOI: 10.3760/cma.j.cn115791-20200403-00185.
    [9]
    ANGULO P, HUI JM, MARCHESINI G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology, 2007, 45(4): 846-854. DOI: 10.1002/hep.21496.
    [10]
    PAN XZ, QI Y, YANG Y. Research advances in liver dysfunction in patients with type 2 diabetes[J]. J Clin Hepatol, 2020, 36(10): 2370-2374. DOI: 10.3969/j.issn.1001-5256.2020.10.046.

    潘秀珍, 戚筠, 杨杨. 2型糖尿病患者合并肝功能异常的研究进展[J]. 临床肝胆病杂志, 2020, 36(10): 2370-2374. DOI: 10.3969/j.issn.1001-5256.2020.10.046.
    [11]
    STEINER DF, CUNNINGHAM D, SPIGELMAN L, et al. Insulin biosynthesis: Evidence for a precursor[J]. Science, 1967, 157(3789): 697-700. DOI: 10.1126/science.157.3789.697.
    [12]
    ROTH J, WHITFORD I, DANKNER R, et al. How the immunoassay transformed C-peptide from a duckling into a swan[J]. Diabetologia, 2012, 55(4): 865-869. DOI: 10.1007/s00125-011-2421-0.
    [13]
    NORDQUIST L, JOHANSSON M. Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications?[J]. Vasc Health Risk Manag, 2008, 4(6): 1283-1288. DOI: 10.2147/vhrm.s3955.
    [14]
    WANG N, WANG Y, ZHANG W, et al. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes[J]. Diabetes Metab Res Rev, 2020, 36(2): e3210. DOI: 10.1002/dmrr.3210.
    [15]
    PINGER CW, ENTWISTLE KE, BELL TM, et al. C-Peptide replacement therapy in type 1 diabetes: Are we in the trough of disillusionment?[J]. Mol Biosyst, 2017, 13(8): 1432-1437. DOI: 10.1039/c7mb00199a.
    [16]
    MANSOUR A, MOHAJERI-TEHRANI MR, SAMADI M, et al. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients[J]. Acta Diabetol, 2019, 56(11): 1199-1207. DOI: 10.1007/s00592-019-01374-x.
    [17]
    AKUTA N, KAWAMURA Y, FUJIYAMA S, et al. Predictors of insulin secretion in Japanese patients with histopathologically-confirmed non-alcoholic fatty liver disease[J]. Intern Med, 2020, 59(3): 329-338. DOI: 10.2169/internalmedicine.3555-19.
    [18]
    ATSAWARUNGRUANGKIT A, CHENBHANICH J, DICKSTEIN G. C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population[J]. World J Gastroenterol, 2018, 24(32): 3663-3670. DOI: 10.3748/wjg.v24.i32.3663.
    [19]
    TILG H, MOSCHEN AR. Inflammatory mechanisms in the regulation of insulin resistance[J]. Mol Med, 2008, 14(3-4): 222-231. DOI: 10.2119/2007-00119.Tilg.
    [20]
    SHPAKOV AO, GRANSTREM OK. C-peptide physiological effects[J]. Ross Fiziol Zh Im I M Sechenova, 2013, 99(2): 196-211.
    [21]
    HUI JM, SUD A, FARRELL GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected][J]. Gastroenterology, 2003, 125(6): 1695-1704. DOI: 10.1053/j.gastro.2003.08.032.
    [22]
    RASCHI E, MAZZOTTI A, POLUZZI E, et al. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: Focus on nonalcoholic fatty liver disease[J]. Expert Opin Pharmacother, 2018, 19(17): 1903-1914. DOI: 10.1080/14656566.2018.1531126.
    [23]
    MUSSO G, CASSADER M, PASCHETTA E, et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A Meta-analysis[J]. JAMA Intern Med, 2017, 177(5): 633-640. DOI: 10.1001/jamainternmed.2016.9607.
    [24]
    CHEN HP, SHIEH JJ, CHANG CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies[J]. Gut, 2013, 62(4): 606-615. DOI: 10.1136/gutjnl-2011-301708.
    [25]
    TSENG CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes[J]. Liver Int, 2018, 38(11): 2018-2027. DOI: 10.1111/liv.13872.
    [26]
    DING QH, SHI DH. Advances on the molecular mechanism of metformin's antitumor effect[J]. Chin J Clin Pharmacol Ther, 2019, 24(3): 350-354. DOI: 10.12092/j.issn.1009-2501.2019.03.019.

    丁秋花, 史道华. 二甲双胍抗肿瘤作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 350-354. DOI: 10.12092/j.issn.1009-2501.2019.03.019.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (590) PDF downloads(31) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return